Movement Alert｜ASYMCHEM Rises 5.33% in Regular Trading, Upcoming Mid-Term Results and Bullish Institutional Sentiment Fuel Rebound

Market Focus08-17

On August 17, ASYMCHEM rose 5.33% in regular trading, trading at HK$121.2/share, with turnover of HK$43.23 million. The stock rebounded after a 5%-plus decline on August 13.

On the news front, ASYMCHEM is scheduled to release its interim results for the six months ended June 30 on August 24. Institutional consensus leans bullish, with 9 out of 10 brokerages issuing buy ratings over the past 90 days and a mean target price of RMB 171.0 for the A-share. The company reported Q1 gross margin of 43.02% and net margin of 16.89%, providing a baseline for upcoming half-year performance assessment.

At the industry level, the CXO sector is entering an earnings delivery phase. Global biopharma financing totaled US$26.75 billion in H1, up 58.5% year-over-year, while ADC, peptide, and oligonucleotide pipelines continue to drive outsourcing demand. Peer Wuxi AppTec previously reported H1 revenue of RMB 28.9 billion, up 38.93% year-over-year, lifting the entire contract research and manufacturing sector. ASYMCHEM also announced a RMB 1.24 billion capital injection into its biologics subsidiary to expand large-molecule CDMO capacity, signaling strategic commitment to high-growth segments.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1142543677?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-17 10:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1142543677","market":"us","top_or_hot":-1,"title":"Movement Alert｜ASYMCHEM Rises 5.33% in Regular Trading, Upcoming Mid-Term Results and Bullish Institutional Sentiment Fuel Rebound","media":"Market Focus","content":"<p><p>On August 17, ASYMCHEM rose 5.33% in regular trading, trading at HK$121.2/share, with turnover of HK$43.23 million. The stock rebounded after a 5%-plus decline on August 13.</p><p>On the news front, ASYMCHEM is scheduled to release its interim results for the six months ended June 30 on August 24. Institutional consensus leans bullish, with 9 out of 10 brokerages issuing buy ratings over the past 90 days and a mean target price of RMB 171.0 for the A-share. The company reported Q1 gross margin of 43.02% and net margin of 16.89%, providing a baseline for upcoming half-year performance assessment.</p><p>At the industry level, the CXO sector is entering an earnings delivery phase. Global biopharma financing totaled US$26.75 billion in H1, up 58.5% year-over-year, while ADC, peptide, and oligonucleotide pipelines continue to drive outsourcing demand. Peer Wuxi AppTec previously reported H1 revenue of RMB 28.9 billion, up 38.93% year-over-year, lifting the entire contract research and manufacturing sector. ASYMCHEM also announced a RMB 1.24 billion capital injection into its biologics subsidiary to expand large-molecule CDMO capacity, signaling strategic commitment to high-growth segments.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜ASYMCHEM Rises 5.33% in Regular Trading, Upcoming Mid-Term Results and Bullish Institutional Sentiment Fuel Rebound</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜ASYMCHEM Rises 5.33% in Regular Trading, Upcoming Mid-Term Results and Bullish Institutional Sentiment Fuel Rebound\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-08-17 10:06</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On August 17, ASYMCHEM rose 5.33% in regular trading, trading at HK$121.2/share, with turnover of HK$43.23 million. The stock rebounded after a 5%-plus decline on August 13.</p><p>On the news front, ASYMCHEM is scheduled to release its interim results for the six months ended June 30 on August 24. Institutional consensus leans bullish, with 9 out of 10 brokerages issuing buy ratings over the past 90 days and a mean target price of RMB 171.0 for the A-share. The company reported Q1 gross margin of 43.02% and net margin of 16.89%, providing a baseline for upcoming half-year performance assessment.</p><p>At the industry level, the CXO sector is entering an earnings delivery phase. Global biopharma financing totaled US$26.75 billion in H1, up 58.5% year-over-year, while ADC, peptide, and oligonucleotide pipelines continue to drive outsourcing demand. Peer Wuxi AppTec previously reported H1 revenue of RMB 28.9 billion, up 38.93% year-over-year, lifting the entire contract research and manufacturing sector. ASYMCHEM also announced a RMB 1.24 billion capital injection into its biologics subsidiary to expand large-molecule CDMO capacity, signaling strategic commitment to high-growth segments.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"06821","symbol_name":"凯莱英","start_time":0,"source_url":"","article_id":"1142543677","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1142543677","pubTimestamp":1786932396,"columns":[{"name":"Data Report","id":30,"label_key":"dataReport"}],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On August 17, ASYMCHEM rose 5.33% in regular trading, trading at HK$121.2/share, with turnover of HK$43.23 million. The stock rebounded after a 5%-plus decline on August 13.On the news front,...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"06821":"凯莱英"},"translate_title":"走势警报|凯莱英常规交易上涨5.33%，即将公布的中期业绩和看涨的机构情绪推动反弹","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06821":1},"content_text":"On August 17, ASYMCHEM rose 5.33% in regular trading, trading at HK$121.2/share, with turnover of HK$43.23 million. The stock rebounded after a 5%-plus decline on August 13.On the news front, ASYMCHEM is scheduled to release its interim results for the six months ended June 30 on August 24. Institutional consensus leans bullish, with 9 out of 10 brokerages issuing buy ratings over the past 90 days and a mean target price of RMB 171.0 for the A-share. The company reported Q1 gross margin of 43.02% and net margin of 16.89%, providing a baseline for upcoming half-year performance assessment.At the industry level, the CXO sector is entering an earnings delivery phase. Global biopharma financing totaled US$26.75 billion in H1, up 58.5% year-over-year, while ADC, peptide, and oligonucleotide pipelines continue to drive outsourcing demand. Peer Wuxi AppTec previously reported H1 revenue of RMB 28.9 billion, up 38.93% year-over-year, lifting the entire contract research and manufacturing sector. ASYMCHEM also announced a RMB 1.24 billion capital injection into its biologics subsidiary to expand large-molecule CDMO capacity, signaling strategic commitment to high-growth segments.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1142543677","isCrawlerRequest":true}